Ajanta Pharma gets USFDA observations for Dahej facilityAJANTPHARM - 1963 Change: 43.40 (2.26 %)
News: USFDA inspected Ajanta Pharma’s Dahej facility from September 5-9, 2022. It concluded with a Form 483 with two procedural observations. Ajanta Pharma is in the process of responding to the same within the stipulated time prescribed by USFDA.
View: Of the seven manufacturing facilities, Paithan and Dahej are earmarked for the US. In FY22, US contributed 21% to the topline. Regulatory clearance for Dahej will be a key monitorable for Ajanta Pharma's US business.